2025 Research Updates in Lymphoma

Saturday, October 18, 2025, 7:30 AM - Sunday, October 19, 2025, 3:00 PM PST, Cedars-Sinai Advanced Health Science Pavilion Educational Center, Los Angeles, CA


This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, "How I Treat" sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.

1. Recognize the utility of molecular testing in the classification and treatment of lymphoma
2. Identify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma
3. Describe new treatments under development including bi specific antibodies and CART therapies
4. Collaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making

In-Person Fees
In-Person: Healthcare Professional Fee - $0.00
In-Person: Industry Attendee (No Exhibit Booth) - $550.00

Virtual Fees
Virtual: Healthcare Professional Fee - $0.00
Virtual: Industry Attendee (No Exhibit Booth) - $550.00

In support of improving patient care, Cedars-Sinai is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement
Cedars-Sinai designates this Live Activity for a maximum of 10.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician AMA Attendance
Attendance credit will be provided to other healthcare professionals upon the fulfillment of attendance requirements. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.  

AMA PRA Category 1 Credit(s)™ (MD, DO) (10.00 hours), ANCC (10.00 hours), IPCE (10.00 hours), Non-Physician AMA Attendance (10.00 hours)

Mitigation of Relevant Financial Relationships

Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.